Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Breast Cancer

  Free Subscription


31.08.2020

1 AJR Am J Roentgenol
1 Ann Oncol
1 Ann Surg Oncol
2 BMC Cancer
1 BMJ
1 Breast Cancer (Auckl)
5 Breast Cancer Res Treat
4 Breast J
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
5 Cancer Res
1 Carcinogenesis
2 Clin Breast Cancer
3 Clin Cancer Res
1 Eur Radiol
2 Int J Cancer
1 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
1 J Natl Cancer Inst
1 Lancet Glob Health
2 Lancet Oncol
2 NPJ Breast Cancer
3 Oncogene
1 PLoS Comput Biol
5 PLoS One
1 Radiother Oncol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. CHAPMAN MC, Hayward JH, Woodard GA, Joe BN, et al
    The Role of Breast MRI in Detecting Asymptomatic Recurrence After Therapeutic Mastectomy.
    AJR Am J Roentgenol. 2020 May 6:1-8. doi: 10.2214/AJR.19.21640.
    PubMed         Abstract available


    Ann Oncol

  2. LITTON JK, Hurvitz SA, Mina LA, Rugo HS, et al
    Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Ann Oncol. 2020 Aug 20. pii: S0923-7534(20)42106.
    PubMed         Abstract available


    Ann Surg Oncol

  3. ASAAD M, Meaike J, Yonkus J, Hoskin T, et al
    Breast Reconstruction in the Setting of Stage 4 Breast Cancer: Is It Worthwhile?
    Ann Surg Oncol. 2020 Aug 25. pii: 10.1245/s10434-020-08879.
    PubMed         Abstract available


    BMC Cancer

  4. WANG S, Wen G, Tang Y, Yang Y, et al
    Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions.
    BMC Cancer. 2020;20:792.
    PubMed         Abstract available

  5. MURATOV S, Canelo-Aybar C, Tarride JE, Alonso-Coello P, et al
    Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators.
    BMC Cancer. 2020;20:795.
    PubMed         Abstract available


    BMJ

  6. MAHASE E
    Trial to extend breast cancer screening won't resume randomisation after pandemic.
    BMJ. 2020;370:m3337.
    PubMed        


    Breast Cancer (Auckl)

  7. NAHLEH ZA, Elimimian EB, Elson LC, Hobbs B, et al
    Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database.
    Breast Cancer (Auckl). 2020;14:1178223420945694.
    PubMed         Abstract available


    Breast Cancer Res Treat

  8. ERBER R, Rubner M, Davenport S, Hauke S, et al
    Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients.
    Breast Cancer Res Treat. 2020 Aug 27. pii: 10.1007/s10549-020-05865.
    PubMed         Abstract available

  9. PIZZATO M, Carioli G, Rosso S, Zanetti R, et al
    The impact of selected risk factors among breast cancer molecular subtypes: a case-only study.
    Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05820.
    PubMed         Abstract available

  10. HERMANN N, Klil-Drori A, Angarita FA, Westergard S, et al
    Screening women at high risk for breast cancer: one program fits all? : Subgroup analysis of a large population high risk breast screening program.
    Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05895.
    PubMed         Abstract available

  11. SUNDBOLL J, Farkas DK, Adelborg K, Schapira L, et al
    Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study.
    Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05879.
    PubMed         Abstract available

  12. TRANT AA, Walz L, Allen W, DeJesus J, et al
    Increasing accrual of minority patients in breast cancer clinical trials.
    Breast Cancer Res Treat. 2020 Aug 25. pii: 10.1007/s10549-020-05873.
    PubMed         Abstract available


    Breast J

  13. GUTKIN PM, Kapp DS, von Eyben R, Dirbas FM, et al
    Impact of mastectomy for breast cancer on spinal curvature: Considerations when treating patients with scoliosis.
    Breast J. 2020 Aug 25. doi: 10.1111/tbj.14018.
    PubMed         Abstract available

  14. MASOOD S
    The role of pathologists in recognition of morphologic and biologic features of genetically mutated breast cancer.
    Breast J. 2020;26:1583-1588.
    PubMed         Abstract available

  15. YU J, Olsen MA, Margenthaler JA
    Indications for readmission following mastectomy for breast cancer: An assessment of patient and operative factors.
    Breast J. 2020 Aug 26. doi: 10.1111/tbj.14029.
    PubMed         Abstract available

  16. GHANI S, Sochat M, Luo J, Tao Y, et al
    Characteristics of male triple negative breast cancer: A population-based study.
    Breast J. 2020 Aug 27. doi: 10.1111/tbj.14023.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  17. SAUDER CAM, Li Q, Othieno A, Cruz D, et al
    Characteristics and Outcomes for Secondary Breast Cancer in Childhood, Adolescent, and Young Adult Cancer Survivors Treated with Radiation.
    Cancer Epidemiol Biomarkers Prev. 2020 Aug 26. pii: 1055-9965.EPI-20-0260.
    PubMed         Abstract available


    Cancer Lett

  18. ZHAO CC, Zhan MN, Liu WT, Jiao Y, et al
    Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
    Cancer Lett. 2020 Aug 20. pii: S0304-3835(20)30419.
    PubMed         Abstract available

  19. LOBO YA, Bonazza C, Batista FP, Castro RA, et al
    EcTI impairs survival and proliferation pathways in triple-negative breast cancer by modulating cell-glycosaminoglycans and inflammatory cytokines.
    Cancer Lett. 2020 Aug 22. pii: S0304-3835(20)30431.
    PubMed         Abstract available


    Cancer Res

  20. KARIMIAN A, Ji NT, Song H, Sgouros G, et al
    Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.
    Cancer Res. 2020;80:868-876.
    PubMed         Abstract available

  21. ABRAHAMSSON A, Vazquez Rodriguez G, Dabrosin C
    Fulvestrant-mediated attenuation of the innate immune response decreases ER+ breast cancer growth in vivo more effectively than tamoxifen.
    Cancer Res. 2020 Aug 27. pii: 0008-5472.CAN-20-1705.
    PubMed         Abstract available

  22. PRZANOWSKI P, Lou S, Tihagam RD, Mondal T, et al
    Oncogenic TRIM37 links chemoresistance and metastatic fate in triple-negative breast cancer.
    Cancer Res. 2020 Aug 27. pii: 0008-5472.CAN-20-1459.
    PubMed         Abstract available

  23. FANG Z, Wang Y, Wang Z, Xu M, et al
    ERINA is an estrogen-responsive lncRNA that drives breast cancer through the E2F1/RB1 pathway.
    Cancer Res. 2020 Aug 21. pii: 0008-5472.CAN-20-1031.
    PubMed         Abstract available

  24. BERI P, Popravko A, Yeoman B, Kumar A, et al
    Cell Adhesiveness Serves as a Biophysical Marker for Metastatic Potential.
    Cancer Res. 2020;80:901-911.
    PubMed         Abstract available


    Carcinogenesis

  25. CHATTERJEE S, Chatterjee A, Jana S, Dey S, et al
    Transforming growth factor beta orchestrates PD-L1 enrichment in tumor derived exosomes and mediates CD8 T cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Carcinogenesis. 2020 Aug 24. pii: 5896493. doi: 10.1093.
    PubMed         Abstract available


    Clin Breast Cancer

  26. EARLY AP, Moon W
    Breast Cancer and Secondary Cancer Recurrences After Autologous Tissue Reconstruction.
    Clin Breast Cancer. 2020 Aug 3. pii: S1526-8209(20)30181.
    PubMed         Abstract available

  27. GADDAM S, Heller SL, Babb JS, Gao Y, et al
    Male Breast Cancer Risk Assessment and Screening Recommendations in High-Risk Men Who Undergo Genetic Counseling and Multigene Panel Testing.
    Clin Breast Cancer. 2020 Jul 25. pii: S1526-8209(20)30180.
    PubMed         Abstract available


    Clin Cancer Res

  28. YANG H, Shu Z, Jiang Y, Mao W, et al
    6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
    Clin Cancer Res. 2019 Aug 7. pii: 1078-0432.CCR-18-3448.
    PubMed         Abstract available

  29. AXELROD ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, et al
    Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer.
    Clin Cancer Res. 2020 Aug 21. pii: 1078-0432.CCR-19-3685.
    PubMed         Abstract available

  30. GUARNERI V, Dieci MV, Bisagni G, Brandes AA, et al
    PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype.
    Clin Cancer Res. 2020 Aug 25. pii: 1078-0432.CCR-20-1731.
    PubMed         Abstract available


    Eur Radiol

  31. GAO Y, Luo Y, Zhao C, Xiao M, et al
    Nomogram based on radiomics analysis of primary breast cancer ultrasound images: prediction of axillary lymph node tumor burden in patients.
    Eur Radiol. 2020 Aug 26. pii: 10.1007/s00330-020-07181.
    PubMed         Abstract available


    Int J Cancer

  32. UGALDE-MORALES E, Grassmann F, Humphreys K, Li J, et al
    Association between breast cancer risk and disease aggressiveness: characterizing underlying gene expression patterns.
    Int J Cancer. 2020 Aug 28. doi: 10.1002/ijc.33270.
    PubMed         Abstract available

  33. WANG F, Meszoely I, Pal T, Mayer IA, et al
    Radiotherapy After Breast Conserving Surgery for Elderly Patients with Early-Stage Breast Cancer: A National Registry Based Study.
    Int J Cancer. 2020 Aug 24. doi: 10.1002/ijc.33265.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  34. LALANI N, Voduc KD, Jimenez RB, Levasseur N, et al
    Breast cancer molecular subtype as a predictor of radiotherapy fractionation sensitivity.
    Int J Radiat Oncol Biol Phys. 2020 Aug 24. pii: S0360-3016(20)34133.
    PubMed         Abstract available


    J Clin Oncol

  35. JOHNSTON SRD, Hegg R, Im SA, Park IH, et al
    Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Br
    J Clin Oncol. 2020 Aug 21:JCO2001894. doi: 10.1200/JCO.20.01894.
    PubMed         Abstract available

  36. MEATTINI I, Marrazzo L, Saieva C, Desideri I, et al
    Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial.
    J Clin Oncol. 2020 Aug 24:JCO2000650. doi: 10.1200/JCO.20.00650.
    PubMed         Abstract available


    J Natl Cancer Inst

  37. VAN DEN BROEK JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, et al
    Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
    J Natl Cancer Inst. 2020 Aug 27. pii: 5898201. doi: 10.1093.
    PubMed         Abstract available


    Lancet Glob Health

  38. MCCORMACK V, McKenzie F, Foerster M, Zietsman A, et al
    Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): a prospective cohort study.
    Lancet Glob Health. 2020;8:e1203-e1212.
    PubMed         Abstract available


    Lancet Oncol

  39. WEBER WP, Morrow M, Boniface J, Pusic A, et al
    Knowledge gaps in oncoplastic breast surgery.
    Lancet Oncol. 2020;21:e375-e385.
    PubMed         Abstract available

  40. KAIDAR-PERSON O, Kuhn T, Poortmans P
    Should we worry about residual disease after mastectomy?
    Lancet Oncol. 2020;21:1011-1013.
    PubMed        


    NPJ Breast Cancer

  41. WANG K, Sun JZ, Wu QX, Li ZY, et al
    Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study.
    NPJ Breast Cancer. 2020;6:36.
    PubMed         Abstract available

  42. KANTOR O, Wong S, Weiss A, Metzger O, et al
    Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer.
    NPJ Breast Cancer. 2020;6:35.
    PubMed         Abstract available


    Oncogene

  43. CHERVO MF, Cordo Russo RI, Petrillo E, Izzo F, et al
    Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth.
    Oncogene. 2020 Aug 25. pii: 10.1038/s41388-020-01430.
    PubMed         Abstract available

  44. VERNIER M, McGuirk S, Dufour CR, Wan L, et al
    Inhibition of DNMT1 and ERRalpha crosstalk suppresses breast cancer via derepression of IRF4.
    Oncogene. 2020 Aug 27. pii: 10.1038/s41388-020-01438.
    PubMed         Abstract available

  45. WANG J, Wang G, Cheng D, Huang S, et al
    Her2 promotes early dissemination of breast cancer by suppressing the p38-MK2-Hsp27 pathway that is targetable by Wip1 inhibition.
    Oncogene. 2020 Aug 26. pii: 10.1038/s41388-020-01437.
    PubMed         Abstract available


    PLoS Comput Biol

  46. LI X, Liu L, Goodall GJ, Schreiber A, et al
    A novel single-cell based method for breast cancer prognosis.
    PLoS Comput Biol. 2020;16:e1008133.
    PubMed         Abstract available


    PLoS One

  47. JO W
    Funding sources and breast cancer research frame.
    PLoS One. 2020;15:e0238026.
    PubMed         Abstract available

  48. DE-LA-CRUZ-KU G, Luyo M, Morante Z, Enriquez D, et al
    Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience.
    PLoS One. 2020;15:e0237811.
    PubMed         Abstract available

  49. HOU H, Lyu Y, Jiang J, Wang M, et al
    Peripheral blood transcriptome identifies high-risk benign and malignant breast lesions.
    PLoS One. 2020;15:e0233713.
    PubMed         Abstract available

  50. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
    Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
    PLoS One. 2020;15:e0233397.
    PubMed         Abstract available

  51. JANK P, Gehlhaar C, Bianca L, Caterina F, et al
    MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
    PLoS One. 2020;15:e0238021.
    PubMed         Abstract available


    Radiother Oncol

  52. LAUGAARD LORENZEN E, Christian Rehammar J, Jensen MB, Ewertz M, et al
    Radiation-induced risk of ischemic heart disease following breast cancer radiotherapy in Denmark, 1977-2005.
    Radiother Oncol. 2020 Aug 25. pii: S0167-8140(20)30725.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: